FSD Pharma Inc.
HUGE · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $3 | $4 | $4 | $4 |
| Gross Profit | -$3 | -$4 | -$4 | -$4 |
| % Margin | – | – | – | – |
| R&D Expenses | $4 | $7 | $6 | $8 |
| G&A Expenses | $12 | $16 | $23 | $18 |
| SG&A Expenses | $13 | $16 | $23 | $18 |
| Sales & Mktg Exp. | $1 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $5 | $4 | $5 |
| Operating Expenses | $17 | $27 | $34 | $31 |
| Operating Income | -$20 | -$27 | -$34 | -$31 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1 | $1 | -$0 | $2 |
| Pre-Tax Income | -$19 | -$27 | -$34 | -$28 |
| Tax Expense | $0 | -$3 | $1 | $4 |
| Net Income | -$19 | -$23 | -$35 | -$33 |
| % Margin | – | – | – | – |
| EPS | -0.47 | -0.6 | -1.01 | -2.72 |
| % Growth | 21.7% | 40.6% | 62.9% | – |
| EPS Diluted | -0.47 | -0.6 | -1.01 | -2.72 |
| Weighted Avg Shares Out | 40 | 39 | 35 | 12 |
| Weighted Avg Shares Out Dil | 40 | 39 | 35 | 12 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $3 | $5 | $4 | $4 |
| EBITDA | -$16 | -$22 | -$30 | -$24 |
| % Margin | – | – | – | – |